Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstract for Metastatic Uveal Melanoma at American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Rhea-AI Summary

Provectus (OTCQB: PVCT) announced that data from its ongoing clinical trial of PV-10, an investigational cancer immunotherapy, will be presented at the ASCO 2022 annual meeting from June 3-7, 2022, in Chicago. The focus is on treating metastatic uveal melanoma (mUM) to the liver. Key details include:

• Abstract Title: Metabolic complete responses in mUM patients treated with PV-10
• Abstract Number: 9543
• Session Date: June 6, 2022, 1:15-4:15 PM CDT

This presentation highlights the potential of PV-10 in oncology.

Positive

• Presentation of clinical trial data at a prestigious event (ASCO 2022), which could enhance visibility and credibility.
• Focus on a specific cancer type (metastatic uveal melanoma), allowing for targeted investor interest.

Negative

• No concrete financial metrics or results provided which raises questions about the trial's success.
• Risks associated with the ongoing clinical trials, including the possibility of not achieving health authority approvals.

KNOXVILLE, TN, April 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10, a formulation of Provectus’ immunogenic-small molecule and pharmaceutical-grade rose bengal sodium (RBS), for the treatment of uveal melanoma metastatic to the liver (mUM) (NCT00986661) will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2022 annual meeting, to be held June 3-7, 2022 in Chicago, Illinois.

ASCO Presentation Details:

• Abstract Title: Metabolic complete responses (mCR) in metastatic uveal melanoma (mUM) patients treated with image-guided injection (IGI) of PV-10
• Abstract Number for Publication: 9543
• Session Title: Melanoma/Skin Cancers
• Session Date and Time: June 6, 2022, 1:15-4:15 pm CDT

About Provectus

Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes (HXs). The Company’s lead molecule is RBS. A second HX molecule has been synthesized.

Provectus’ drug discovery and development programs include investigational drugs and drug targets in oncology (clinical-stage), dermatology (clinical-stage), hematology, virology, microbiology, ophthalmology (clinical-stage), and animal health, and use multiple routes of administration, such as intralesional (IL), topical (.top), oral (P.O.), inhaled (.inh), intranasal (IN), and intravenous (IV).

Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.

FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

###

Contact:

Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999

FAQ

What is Provectus's PV-10 trial about?

The PV-10 trial focuses on an investigational cancer immunotherapy for treating metastatic uveal melanoma to the liver.

When will Provectus present its trial data?

Provectus will present its trial data at the ASCO 2022 meeting on June 6, 2022.

What are the key details of the ASCO 2022 presentation?

The presentation includes the abstract title 'Metabolic complete responses in metastatic uveal melanoma patients treated with PV-10' and abstract number 9543.

What are the potential risks of PV-10 based on the press release?

The press release highlights risks such as the lack of established safety and efficacy for PV-10 and the possibility of not achieving health authority approvals.

What is the significance of the ASCO 2022 meeting for Provectus?

The ASCO meeting provides a platform for Provectus to showcase its clinical trial results, potentially attracting investor interest and enhancing its reputation.